Author(s)

Mengshan Yan, Bitian Zhang, Chuyun Zhao

Corresponding Author

Chuyun Zhao

ABSTRACT

The Bcl-2 protein family plays an important role in regulating cell apoptosis, including proteins that inhibit apoptosis and promote apoptosis. In the process of tumorigenesis, the expression of anti-apoptotic proteins increases, and the expression of pro-apoptotic proteins decreases. The overexpression of anti-apoptotic Bcl-2 family proteins is closely related to the pathology and drug resistance of various hematopoietic malignancies and solid tumours. The overexpression of Bcl-2 protein provides conditions for the long-term survival of tumour cells, which can enhance the resistance of mutant cells to gene damage, so that abnormal cells with DNA damage cannot be identified and eliminated, and programmed cell apoptosis is inhibited. This leads to the occurrence of tumours. In the treatment of tumours, this protein site can be used as a target for targeted tumours treatment to achieve the effect of strong specificity and less adverse effects. The research on Bcl-2 inhibitor drugs has made great progress in recent years. This article reviews the application of Bcl-2 inhibitors and the drugs in targeted anti-tumour therapy in recent years at the gene and protein level, explores the advantages and disadvantages of this therapy and provides the basis for better targeted anti-tumour therapy in the future.

KEYWORDS

Bcl-2 proteins, overexpression, Bcl-2 inhibitors, apoptosis, anti-tumour therapy